Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
MVM Partners LLP, founded in 1997, operates from its offices in London and Boston. The firm has built a strong reputation in the healthcare and life sciences sectors, focusing on innovative products that address significant unmet needs. With nearly three decades of experience, MVM has successfully navigated the complexities of healthcare investing, establishing a concentrated portfolio of companies with high growth potential.
As of now, MVM manages assets totaling over $1 billion, with its latest fund, Fund V, closing at $325 million in 2020. The firm has a global investment strategy, primarily targeting North America and Europe, and has expanded its reach into the Middle East and Asia. MVM's commitment to healthcare innovation is evident in its active engagement with portfolio companies, helping them scale and achieve their market potential.
MVM Partners invests across a wide range of sectors within healthcare and life sciences, including medical devices, pharmaceuticals, diagnostics, digital health, health IT, life science tools, contract research, and contract manufacturing. The firm typically targets companies that demonstrate high growth potential and possess differentiated technologies that can address significant unmet needs in large markets.
Investment sizes generally range from $20 million to $100 million per portfolio company, with the flexibility to make larger investments in select cases. MVM focuses on later-stage investments, including seed, Series A, Series B, Series C, and growth equity. The firm seeks to partner with management teams to drive growth, make strategic acquisitions, and establish new standards of care in the healthcare sector.
MVM Partners maintains a concentrated portfolio of innovative healthcare companies. Notable former portfolio companies include:
Recent investments include:
Neil Akhurst: Partner at MVM Partners, part of the healthcare investment team with extensive experience in the sector.
Eric Bednarski: Partner focused on healthcare investments, bringing a wealth of knowledge to the firm.
Thomas Casdagli: Partner with a strong background in healthcare investing, contributing to MVM's strategic direction.
Conrad Crans: Team member involved in healthcare investments, supporting portfolio companies.
Eric Fritz: Team member focused on investment opportunities within healthcare.
Hugo Harrod: Partner with expertise in healthcare investments, actively involved in portfolio management.
Stephen Reeders: Managing Partner and senior healthcare investor, guiding MVM's investment strategy.
Jack Tanaka: Partner known for his insights into rare-disease medicine access across Europe.
Other team members include Liz Butler, Orlanda Bryars, Kevin Cheng, Kyle Dempsey, Thangam Jayaram, Talia Kirschbaum, Isabella Mihov, Chris Murray, Shalima Raza, Arantza Rodriguez, and Addison Van Emon, who contribute across various investment, operational, finance, and support roles.
To pitch MVM Partners, founders should send their proposals via email to info@mvm.com. A comprehensive pitch deck is essential, detailing the startup's technology, market potential, and team qualifications. MVM prefers clear and concise presentations that outline the business model and growth strategy.
Response times may vary, but founders should expect a thorough review process. Warm introductions can enhance the chances of receiving a timely response, so leveraging connections within the healthcare sector may be beneficial.
In February 2026, MVM Partners announced an investment in Neurent Medical, highlighting its ongoing commitment to innovative healthcare solutions.
In November 2025, MVM led an €32M Series A growth investment in Avanzanite Bioscience, a company focused on expanding access to rare-disease medicines across Europe.
In August 2025, MVM participated in an $80M Series B investment in ProVerum, which is developing a minimally invasive urology device.
Additionally, MVM reported a $37M Series D investment in GT Medical Technologies in January 2025, further demonstrating its active engagement in the healthcare sector.
What are MVM Partners' investment criteria?
MVM Partners focuses on high-growth healthcare businesses that address significant unmet needs in large markets. They seek companies with differentiated technology and durable protection against competition.
How can I pitch MVM Partners?
Founders can reach out via email at info@mvm.com. A well-prepared pitch deck should include details about the technology, market potential, and team.
What is the typical check size for investments?
MVM typically invests between $20 million and $100 million in each portfolio company, with the capacity for larger investments in select circumstances.
What stages does MVM Partners invest in?
The firm invests across various stages, including seed, Series A, Series B, Series C, and growth equity.
What geographic areas does MVM focus on?
MVM Partners has a global investment focus, particularly in North America and Europe, with teams in Boston, London, and the San Francisco Bay Area.
What kind of support does MVM provide to portfolio companies?
MVM collaborates closely with management teams to drive growth, make strategic acquisitions, and establish new standards of care, leveraging its extensive industry expertise.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.